Zogenix to Present at Stifel 2018 Healthcare Conference
07. November 2018 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix to Release Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 8
01. November 2018 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
01. Oktober 2018 17:07 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix to Present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
25. September 2018 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04. September 2018 16:38 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durable Reduction in Seizure Frequency in Patients With Lennox-Gastaut Syndrome
04. September 2018 08:00 ET
|
Zogenix, Inc.
67% of Patients Achieved At Least a 50% Reduction in Convulsive Seizures Global Phase 3 Randomized, Controlled Study in LGS Currently Enrolling Patients EMERYVILLE, Calif., Sept. 04, 2018 (GLOBE...
Zogenix Announces New Data on Psychological and Socioeconomic Impact of Dravet Syndrome and Other Epileptic Encephalopathies at 13th European Congress on Epileptology
30. August 2018 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Prices Public Offering of Common Stock
07. August 2018 18:21 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Announces Proposed Public Offering of 6,000,000 Shares of Common Stock
06. August 2018 17:14 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Provides Corporate Update and Reports Second Quarter Financial Results
06. August 2018 16:26 ET
|
Zogenix, Inc.
Reported positive top-line results from second pivotal Phase 3 trial of ZX008 in patients with Dravet syndrome, Study 1504 Submission of U.S. and EU regulatory filings for ZX008 in Dravet syndrome...